In This Article:
NEW YORK, NY / ACCESSWIRE / May 28, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Sprint Corporation (NYSE:S)
Class Period: January 31, 2019 - April 16, 2019
Deadline: June 21, 2019
For more info: www.bgandg.com/s
The complaint alleges that during the Class Period, defendants made materially false and misleading statements regarding the number of net postpaid subscriber additions in its Form 10-Q filing with the Securities and Exchange Commission ("SEC") for the period ending December 31, 2018 (the "10-Q"). Specifically, the Company highlighted in the 10-Q that it had made 309,000 total postpaid net additions - but failed to disclose that these increases were
Boston Scientific Corporation (BSX)
Class Period: February 26, 2015 - April 16, 2019
Deadline: June 24, 2019
For more info: www.bgandg.com/bsx
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Boston Scientific's surgical mesh products indicated for the transvaginal repair of POP were unsafe; (ii) accordingly, Boston Scientific's continued marketing and sales of these devices in the United States was unlikely to be sustainable; (iii) separately, the Company had sold vaginal mesh implants containing counterfeit or adulterated resin products imported from China; (iv) the foregoing conduct subjected the Company to a heightened risk of regulatory scrutiny and/or government investigations; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Indivior PLC (INVVY)
Class Period: March 10, 2015 - April 9, 2019
Deadline: June 24, 2019
For more info: www.bgandg.com/invvy